Pacira BioSciences filings document a life sciences company's financial results, governance actions, credit arrangements and manufacturing-related corporate events. Recent Form 8-K reports furnish quarterly and annual results for the commercial portfolio, including EXPAREL, ZILRETTA and iovera, and disclose the company's common stock listing on the Nasdaq Global Select Market under PCRX.
The filing record also covers board composition and committee appointments, non-employee director compensation, senior secured revolving credit facility terms, and exit or disposal activities associated with EXPAREL manufacturing efficiencies and large-scale production suites. These disclosures frame Pacira's capital structure, liquidity arrangements, operating costs, governance and product-manufacturing infrastructure.
Pacira BioSciences is the subject of a planned tender offer by Peach Purchaser Sub Inc., a wholly owned subsidiary of Viatris Inc., for all outstanding shares of Pacira common stock. The offer has not yet commenced and is described in connection with an Agreement and Plan of Merger dated October 8, 2026.
Completion conditions include valid tenders that are not withdrawn representing at least a majority of Pacira shares outstanding immediately following the offer’s expiration, as well as required regulatory approvals. When the offer begins, Viatris will file a Schedule TO and Pacira will file a Schedule 14D-9. The offer materials will be sent to Pacira stockholders at no expense.
Lauren B. Riker, an officer of Pacira BioSciences, Inc. (PCRX), reported a proposed sale of 6,000 common shares on October 8, 2026, with an aggregate market value of $217,920.00. The shares were acquired from the issuer through a stock option exercise for cash on October 8, 2026. The notice lists 39,861,886 common shares outstanding.
Pacira BioSciences, Inc. (PCRX) agreed to be acquired by Viatris Inc. for $36.50 per share in cash, net of applicable withholding taxes and without interest; the announced aggregate equity value is $1.65 billion. Viatris’ wholly owned subsidiary, Peach Purchaser Sub Inc., will make the tender offer, which has not commenced and is to begin no later than 15 business days after the October 8, 2026 agreement date. Conditions include valid tenders, together with purchaser and affiliate holdings, representing at least one share more than 50% of Pacira shares at offer expiration, and expiration or termination of the applicable Hart-Scott-Rodino Act waiting period.
After the offer, the purchaser is to merge into Pacira under Section 251(h) of the Delaware General Corporation Law; Pacira would survive as a wholly owned Viatris subsidiary, with no shareholder vote required for the merger. Closing is expected by the end of 2026, subject to customary conditions, and Pacira’s board unanimously recommends tendering. Pacira reported approximately $746 million in revenue and $177 million in adjusted EBITDA for the 12 months ended June 30, 2026. The agreement provides for a $62.0 million termination fee payable by Pacira to Viatris in specified circumstances, including termination to accept a Superior Offer.
Pacira BioSciences, Inc. is party to an agreement under which Viatris, through its wholly owned subsidiary Peach Purchaser Sub Inc., will offer $36.50 per share in cash for all outstanding Pacira shares, net of applicable withholding taxes and without interest. The tender offer has not yet commenced; once commenced, it will remain open for 10 business days, subject to extension. Payment is conditioned on valid tenders representing at least one share more than 50% of Pacira’s outstanding shares, as well as regulatory and other closing conditions. The offer has no financing condition.
After the offer, Peach Purchaser Sub is to merge into Pacira, which would continue as a wholly owned Viatris subsidiary under Section 251(h) of the Delaware General Corporation Law, with no stockholder vote required. Pacira’s board unanimously recommended that stockholders tender their shares. Either party may terminate if the offer is not completed by April 8, 2027, subject to a conditional automatic extension to July 8, 2027. Pacira would owe Viatris a $62 million termination fee in specified circumstances.
Pacira BioSciences, Inc. (PCRX) reported that its Chief Medical Officer, Jonathan Slonin, sold 3,040 shares of common stock on August 17, 2026 at $23.23 per share in an open-market transaction. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2025. Following this sale, Slonin directly holds 216,383.646 shares of Pacira common stock, which include 511.471 shares acquired through the company’s employee stock purchase plan in June 2026.
Pacira BioSciences, Inc. (PCRX) filed a notice of proposed sale of common stock under Form 144. The filer plans to sell 3,040 shares of Pacira common stock through Fidelity Brokerage Services LLC on 08/17/2026 on the NASDAQ market, with an aggregate market value of $70,619.20 for the proposed sale. The shares to be sold were originally acquired from the issuer, including 214 shares purchased on 06/30/2022 through an Employee Stock Purchase Plan (cash) and 2,826 shares acquired on 07/01/2022 through restricted stock vesting as compensation.
State Street Corporation reported beneficial ownership of common stock of Pacira BioSciences, Inc.. State Street and its investment adviser subsidiaries collectively beneficially own 2,059,977 shares of Pacira common stock, representing 5.2% of the outstanding class.
State Street reports no sole voting or dispositive power over Pacira shares. It has shared voting power over 1,944,697 shares and shared dispositive power over 2,059,977 shares, reflecting holdings managed through entities including SSGA Funds Management, Inc. and various State Street Global Advisors affiliates.
Pacira BioSciences, Inc. reported Q2 2026 total revenues of $192,399 (in thousands), mainly from EXPAREL and ZILRETTA, with net income of $4,653 (in thousands) or $0.12 per diluted share, compared with a net loss a year earlier. Results included a $6.4 million discrete tax benefit from reversing a U.K. valuation allowance.
The company agreed to divest its iovera° cryoanalgesia business to Zimmer for up to $140.0 million, including a $70.0 million upfront payment and up to $70.0 million in revenue-based milestones; the deal closed on July 31, 2026, with $73.6 million cash received after adjustments. Cash and cash equivalents rose to $205,875 (in thousands), supported by $83,140 (in thousands) of operating cash flow, while Pacira repurchased $50,448 (in thousands) of stock and repaid $10,000 (in thousands) on its Revolving Credit Facility, ending the quarter with total debt of $363,124 (in thousands).
Pacira BioSciences reported second quarter 2026 total revenue of $192.4 million, up 6% from $181.1 million a year earlier, led by EXPAREL sales of $147.8 million and ZILRETTA sales of $32.6 million. GAAP net income was $4.7 million, or $0.12 per share, compared with a $4.8 million loss in 2025. Non-GAAP net income was $29.5 million and adjusted EBITDA $48.7 million, both below prior-year levels.
The company completed the divestiture of its iovera° business to Zimmer Biomet for up to $140 million, receiving $73.6 million in cash at closing, and ended the quarter with $251.0 million in cash, cash equivalents and investments. Updated 2026 guidance calls for total revenue of $735–$760 million, including EXPAREL sales of $600–$620 million, non-GAAP gross margin of 77–79%, and lower non-GAAP SG&A expense of $310–$330 million. Pacira also highlighted expanded reimbursement for EXPAREL from UnitedHealthcare and continued clinical progress for its gene therapy candidate PCRX-201.
Pacira BioSciences agreed to divest its iovera° handheld cryoanalgesia device business to Zimmer Biomet for up to $140.0 million, consisting of an upfront $70.0 million payment and up to an additional $70.0 million in revenue-based milestones through December 31, 2031.
Milestones pay out in tranches of $18.5 million, $23.5 million or $28.0 million if annual iovera° net revenue reaches $50.0 million, $60.0 million or $70.0 million in any year from 2027 to 2031. About 66 employees, roughly 8% of Pacira’s workforce, are expected to join Zimmer Biomet.
Pacira plans to use upfront net proceeds to strengthen its balance sheet, including paying down its senior secured revolving credit facility, and will collaborate with Zimmer Biomet on the iovera° spasticity program with potential incremental compensation. Closing is subject to customary conditions and is expected in the third quarter of 2026.